Earlier announcements regarding the opportunity (02 July 2020) indicated Sensera had over 2m USD of orders for development and delivery. Later commentary said orders were subject to FDA EUA. This confused me as the earlier commentary suggested confirmed orders. Perhaps that first order was not subject to FDA EUA and we have delivered an early batch? Cash receipts and revenues suggest otherwise though! I struggle to see how Sensera is going to ramp production without a decent cash injection. Hopefully that comes in the way of non-dilutive funding but i have my reservations given share price performance and silence from management. Hopefully we find out soon!
SE1 Price at posting:
6.6¢ Sentiment: Buy Disclosure: Held
